The incidence of multimorbidity and patterns in accumulation of chronic conditions: A systematic review

Prtha Kudesia1, Banafsheh Salimarouny1, Meagan Stanley2, Martin Fortin3, Moira Stewart4,5, Amanda Terry1,4,5 and Bridget L Ryan4,5

Abstract
Multimorbidity, the presence of 1+ chronic condition in an individual, remains one of the greatest challenges to health on a global scale. Although the prevalence of multimorbidity has been well-established, its incidence is not fully understood. This systematic review determined the incidence of multimorbidity across the lifespan; the order in which chronic conditions accumulate to result in multimorbidity; and cataloged methods used to determine and report accumulation of chronic conditions resulting in multimorbidity. Studies were identified by searching MEDLINE, Embase, CINAHL, and Cochrane electronic databases. Two independent reviewers evaluated studies for inclusion and performed quality assessments. Of 36 included studies, there was high heterogeneity in study design and operational definitions of multimorbidity. Studies reporting incidence (n = 32) reported a median incidence rate of 30.7 per 1,000 person-years (IQR 39.5 per 1,000 person-years) and a median cumulative incidence of 2.8% (IQR 28.7%). Incidence was notably higher for persons with older age and 1+ chronic conditions at baseline. Studies reporting patterns in accumulation of chronic conditions (n = 5) reported hypertensive and heart diseases, and diabetes, as among the common starting conditions resulting in later multimorbidity. Methods used to discern patterns were highly heterogenous, ranging from the use of latent growth trajectories to divisive cluster analyses, and presentation using alluvial plots to cluster trajectories. Studies reporting the incidence of multimorbidity and patterns in accumulation of chronic conditions vary greatly in study designs and definitions used. To allow for more accurate estimations and comparison, studies must be transparent and consistent in operational definitions of multimorbidity applied.

Keywords
Multimorbidity, systematic review, incidence, epidemiology, accumulation

Received 20 April 2021; accepted: 24 June 2021

1 Schulich Interfaculty Program in Public Health, University of Western Ontario, London, Ontario, Canada
2 Allyn & Betty Taylor Library, University of Western Ontario, London, Ontario, Canada
3 Department of Family Medicine and Emergency Medicine, Université de Sherbrooke, Sherbrooke, Québec, Canada
4 Centre for Studies in Family Medicine & Department of Family Medicine, Schulich School of Medicine & Dentistry, University of Western Ontario, London, Ontario, Canada
5 Department of Epidemiology and Biostatistics, Schulich School of Medicine & Dentistry, University of Western Ontario, London, Ontario, Canada

Corresponding author:
Bridget L Ryan, Centre for Studies in Family Medicine & Department of Family Medicine, University of Western Ontario, 1465 Richmond Street, London, Ontario N6G 2M1, Canada.
Email: bryan@uwo.ca

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Introduction

Multimorbidity continues to increase world-wide, presenting one of today’s biggest challenges to individual and population health, and to health systems. Multimorbidity results in poorer patient outcomes and excess mortality. Patients with multimorbidity also present with unique medical care needs; while specialized treatment approaches are appropriate for single diseases, patients with multimorbidity require complex and structured care plans. This poses substantial impacts on disease management, healthcare utilization, and costs. The study of multimorbidity, and its epidemiology, may help in better understanding its development; determine reasons for variations in patient outcomes; and design targeted interventions to manage adverse outcomes of multimorbidity.

Existing literature on the epidemiology of multimorbidity has increased substantially, moving from a nascent body of evidence in the 1970s to a now well-established and distinct field of research. Consistent with a growing area of study, the epidemiological research was concerned first with defining multimorbidity and summarizing studies concerning its prevalence. Determining prevalence has permitted us to quantify the burden of multimorbidity in populations and health care systems. However, prevalence is limited in its ability to tell us when and why people accumulate multimorbidity. In order to better understand the etiology of multimorbidity and to project the healthcare needs of patients with multimorbidity, we must turn our attention to determining its incidence.

The incidence of multimorbidity is, by definition, the incidence of multiple chronic conditions that are accumulated in a particular order. Therefore, it is important to study both the incidence of multimorbidity and the accumulation of its component chronic conditions. Currently, there is a growing body of research addressing incidence of multimorbidity. As well, there is emerging literature using innovative and heterogeneous methods to describe the accumulation of chronic conditions in multimorbidity. Our goal was to summarize available evidence on the incidence of multimorbidity across the lifespan. More specifically, our objectives were: 1. to determine the incidence of multimorbidity overall and by age groups, including children; 2. to determine the order in which people accumulate the component chronic conditions leading to multimorbidity; and 3. to catalog the methods used to assess and report accumulation.

Methods

We conducted a systematic review (registered in PROSPERO, reference no. CRD42020191876) in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and checklist (Supplementary Table S1). An a priori review process was established and followed; this protocol was not published. As this was a systematic review of literature, Research Ethics Board review or approval was not required. There were no participants or patients enrolled and so no consent was needed for participation, or for patient information and images to be published.

Literature search strategy

Following the recommendation from Chapter 4: Searching for and Selecting Studies in the Cochrane Handbook for Systematic Reviews of Interventions, searches of the health-related bibliographic databases, MEDLINE, Embase, CINAHL, and The Cochrane Library were undertaken by the Health & Medicine Librarian (MS1), utilizing both free-text and subject headings (MeSH) to identify an initial batch of relevant and eligible studies reporting incidence of multimorbidity and/or patterns in accumulation of chronic conditions. Databases were searched from inception to May 26, 2020.

Search terms used in the database query for multimorbidity, with its various spelling, were “multimorbidity,” “multimorbidities,” “multi-morbidities,” “multiple morbidities,” “multiple-morbidities,” “multiple chronic diseases” and “multiple chronic conditions.” We searched for incidence and accumulation and their different meanings, using “incidence*,” “accumulation*,” “trajectory*,” “longitudinal,” “acquire*,” “acquisition,” “predict*,” “cohort,” and “epidemiology.” The full search strategy is provided in Supplementary Table S2.

Study selection

After removing duplicates, titles and abstracts of initial search results were screened by the two reviewers (PK, BS) independently for eligibility. Reviewers initially screened two sets of 10 articles and discussed decisions with the senior study coordinator (BLR) to ensure consistency in applying selection criteria. Eligible articles included peer-reviewed studies using primary or secondary quantitative analyses, including mixed methods studies, published in English and/or French language. Studies with participants of all ages, including children, and specifically reporting 1. incidence of multimorbidity and/or 2. patterns in accumulation of chronic conditions as primary or secondary outcomes, were included. Conference presentations, books, letters, editorials, non-human literatures, and abstract-only studies were excluded. Articles deemed suitable for full-text review were identified and full-texts were then reviewed to confirm eligibility criteria by the two reviewers first independently and then collaboratively to reach consensus. Studies which still satisfied inclusion and exclusion criteria upon full-text review were selected for data extraction. Disagreements were initially discussed by reviewers for resolution. The study coordinator worked with reviewers to resolve any disagreement through consensus. Within the articles identified for review, reference
lists were hand-searched for additional articles meeting our criteria.

Quality assessment

The two reviewers independently performed quality assessment using the Newcastle-Ottawa Scale (NOS) for assessing study methodology of non-randomized studies. NOS assessment guidelines were followed and, where dictated by NOS guidelines, some assessment criteria were further defined by study authors as described in Supplementary Table S3. Randomized controlled trials (RCTs) were assessed for study methodology and risk of bias (RoB) using the Cochrane Collaboration’s RoB tool. Of the 36 included studies, 35 observational studies and one RCT underwent quality and risk of bias assessment (Supplementary Table S4). Individual NOS ratings were converted to Agency for Healthcare Research and Quality (AHRQ) standards as one of three levels: Good, Fair, and Poor. A priori scores to exclude studies of low quality were not established in order to include the entire landscape of literature in this review; as such, studies of all scores were included.

Data extraction

The two reviewers independently extracted data from eligible studies following full-text review. A comprehensive data extraction sheet was developed to collect data pertaining to: study characteristics (authors, date of publication, study design, geographic locations, data collection period, follow-up period, data sources, sample size, populations of interest); sample demographics (ages, sex and/or gender, race and/or ethnicity, body mass index (BMI), education levels, smoking status, alcohol consumption levels, physical activity levels, and marital statuses); definitions of multimorbidity; number and selection of conditions included in definitions of multimorbidity; incidence rates and/or cumulative incidences of multimorbidity; patterns in accumulation of chronic conditions; methods used in accumulation studies; and risk factors for multimorbidity. The sheet was pilot tested using three studies. The two reviewers then reconciled any differences, consulting the senior study coordinator as required. Study authors were contacted by email for further information as needed for clarification.

Incidence data were recorded in separate tables for studies reporting incidence rates (IRs) and for studies reporting cumulative incidence. IRs were extracted as the number of incident cases per 1,000 person-years. Results from studies not already reporting per 1,000 person-years were adjusted to meet this format. Cumulative incidence was extracted as a percentage. Results from studies not providing percentages were standardized to meet this format by dividing the incident cases by the number of baseline participants without multimorbidity and multiplying by 100. When multiple IRs were reported, overall IRs across the population were reported in tables if available; additional IRs were not reported; however, in the tables, the availability of additional IRs is noted. If overall IR or cumulative incidence was not available, incidences provided by study authors were presented in the following priority, as available: by age, sex and/or gender, other demographics.

Results

Overview of studies

The process used for study selection is reported in the PRISMA flow diagram (Figure 1) and PRISMA checklist (Supplementary Table S1). We identified 4,579 studies from the initial database searches; all were published between 1976 and 2020. After removing duplicates and non-original articles, 2,926 studies were identified, of which 109 were retained for full-text screening. A total of 73 articles were excluded following full-text review or qualitative synthesis, with reasons; the majority of excluded studies were those that did not report incidence of multimorbidity; reported incidence of specific chronic conditions and not of multimorbidity; and/or did not account for temporal components when determining patterns in accumulation of chronic conditions, amongst other reasons. Of the articles that underwent full-text review, 36 studies were included in further synthesis. No additional articles meeting our inclusion criteria were identified during hand-searches of study reference lists.

Study quality and characteristics

Of the 35 observational studies, most studies (n = 26) were rated as Good quality according to AHRQ standards. Nine studies were ranked as Poor quality due to their omission of information regarding: representativeness of their data, ascertainment of exposure, controlled factors, assessment of outcome, adequacy of follow-up duration, case definition(s), case representativeness, selection strategy(ies), and/or non-response rate(s). RoB assessment for the one RCT yielded low risk (Supplementary Table S5).

Of the 36 included studies, one examined both incidence and accumulation; 31 studies reported only the incidence; and four studies reported only the accumulation of chronic conditions resulting in multimorbidity. Multimorbidity was defined as the presence of ≥2 chronic conditions in all but six studies. Of these six, one study defined multimorbidity as the co-occurrence of 3 conditions and four did not specify a definition (Supplementary Table S6). However, all authors referenced consideration of ≥2 conditions in their prose and/or tables. The number of chronic conditions used to identify multimorbidity varied extensively, ranging between 3 and 506. At the extremes, in one study of accumulation, three conditions were included (cancer, diabetes, and cardiovascular diseases); whereas, in another, 132 clusters of chronic conditions were included.
Table 1 reports the characteristics of the 32 studies that reported incidence of multimorbidity: 14 reported IR and 18 reported cumulative incidence. Studies were heterogeneous across all descriptive variables, including geographical location of study, data collection and follow-up periods, data sources, sample size and population, and demographics. The majority of studies reported either national or local incidence in high income (HIC) (n = 30) or middle income countries (n = 2). The majority of studies sourced data from a combination of sources, and sampled general populations, with the remainder focused on specific patient populations. Samples were generally larger for studies examining general populations. All except two studies included different age groups across the lifespan. The majority of studies did not report race and/or ethnicity (n = 16/36), and, of those that did, there was heterogeneity in the terminology used to describe race and/or ethnicities.

Table 2 reports characteristics of the five studies reporting patterns in accumulation of chronic conditions resulting in multimorbidity. Similar to studies reporting incidence of multimorbidity, accumulation studies were heterogeneous across all descriptive variables, including geographical location of study; data collection and follow-up period; sample population and size; and demographics. The majority of studies reported either national or local patterns in accumulation of chronic conditions in HICs. Most accumulation studies sampled general populations.
| Study, year of publication | Country | Data collection period | Data source | Sample size | Population Age, years (range) | Female, n (%) | Ethnicity |
|---------------------------|---------|------------------------|-------------|-------------|-----------------------------|---------------|-----------|
| Aminisani et al., 2019    | New Zealand | 2006–2016 10.0 years | Self-report (questionnaire) | 1,673 | General population 55–70 | 868 (52) | Māori, Non-Māori (European, Asian, Pacific persons, Other) |
| Bjur et al., 2019         | USA     | 1999–2014 5.0 years | Medical records | 1999 cohort: 15,200 | General population 0–17 | 1,597 (80) | Non-Hispanic white, Other (African-American, Asian-American, Hispanic, Other and/or Unknown) |
| Castilho et al., 2019     | Brazil  | 2003–2014 3.9 years | Medical records | 6,121 | Persons with HIV receiving ART | 6,121 | White, Mixed Black or Black, Other/Unknown/Other |
| Castilho et al., 2020     | USA     | 1998–2015 4.9 years | Medical records | 2,487 | Persons with HIV | 2,487 | White, Black, Other |
| Chan et al., 2019         | United Kingdom | 2001–2010 5.5 years (mean) | Medical records | 844,838 | General population 45–60 | 595,176 (53) | Not specified |
| Dhalwani et al., 2016     | United Kingdom | 2008–2013 232,749 person-months | Self-report (survey), clinical evaluation | 5,476 | General population 18–20 | 2,901 (53) | White, Non-White |
| Dugravot et al., 2020     | United Kingdom | 1985–2017 23.6 years (median) | Self-report (questionnaire), medical records, health insurance records | 6,425 | British civil servants | 1,846 (29) | Not specified |
| Freising et al., 2019     | Denmark, Germany, Italy, Netherlands, Spain, Sweden | 1995–2014 11.0 years (median) | Self-report (survey), medical records | 291,778 | General population 18–50 | 186,564 (64) | Not specified |
| Freising et al., 2020     | United Kingdom | 2014–2016 1.5 years | Medical records | 729 | General population | 729 | Not specified |
| Freising et al., 2020     | Malaysia | 2014–2016 1.5 years | Self-report (survey) | 120,813 | General population | 120,813 | Not specified |
| Freising et al., 2020     | Malaysia | 2014–2016 1.5 years | Self-report (survey) | 729 | General population | 729 | Not specified |
| Freising et al., 2020     | Malaysia | 2014–2016 1.5 years | Self-report (survey) | 729 | General population | 729 | Not specified |
| Freising et al., 2020     | Malaysia | 2014–2016 1.5 years | Self-report (survey) | 729 | General population | 729 | Not specified |
| Study, year of publication | Country | Data collection period | Follow-up period | Data source | Sample size | Population | Age, years (range) | Female, n (%) | Ethnicity |
|---------------------------|---------|-----------------------|------------------|-------------|-------------|------------|-------------------|---------------|-----------|
| Demirchyan et al., 2013   | Armenia| 1990–2012             | 22.0 years       | Self-report (survey), clinical evaluation | 597         | Survivors of the 1988 Armenian earthquake | 39–90      | 491 (68) | Not specified |
| Guaraldi et al., 2015     | Italy   | 2003–2014             | 8,206 person-years | Medical records, clinical evaluation, laboratory values | 2,383       | Persons with HIV | 46 (mean) | 867 (32) | Not specified |
| Holmman et al., 2019      | Sweden, Netherlands, Germany | Not specified | 4–20 years following birth | Self-report (questionnaire) | 18,451 | General population from 5 birth cohorts | 4–20 | 9,040 (49) | Not specified |
| Marengoni et al., 2018    | Finland | 2009–2011             | 2.0 years        | Self-report (questionnaire) | 489       | General population | 60–77    | 499 (47) | Not specified |
| Mounce et al., 2018       | United Kingdom | 2002–2013 | 10.1 years (mean) | Self-report (questionnaire), interview, clinical evaluation | 3,011 | General population | ≥50 | 1,593 (53) | Not specified |
| Niedzwiedz et al., 2019   | USA     | 2008–2014             | 6.0 years (mean) | Self-report (questionnaire), laboratory values | 1,989 | General population | 50–100   | 1,173 (59) | Non-Hispanic White, Non-Hispanic Black, Hispanic, Other |
| Ryan et al., 2018         | Ireland | 2010–2012             | 2.0 years        | Self-report (questionnaire) | 2,235 | General population | ≥50 | 1,120 (50) | Not specified |
| Salloum et al., 2019      | USA, Canada | 1970–1999 | 15.0 years | Medical records, self-report (questionnaire) | 997    | Survivors of childhood cancer (medulloblastoma) | 0–21 | 389 (39) | Non-Hispanic White, Non-Hispanic Black, Hispanic, Other |
| Singh-Manouex et al., 2018| United Kingdom | 1985–2002 | 23.7 years (mean) | Medical records, clinical examination, laboratory values, self-report (questionnaire) | 8,270 | General population | 50 | 2,720 (33) | White, Non-White |
| Tomasdottir et al., 2016  | Norway  | 1995–2008             | 11.0 years (mean) | Self-report (questionnaire), clinical evaluation, laboratory values, self-report (questionnaire) | 20,365 | General population | 20–59 | 10,938 (54) | Not specified |
| Ungprasert et al., 2017   | USA     | 1976–2013             | Cases: 12.9 years (median), Comparators: 15.6 years (median) | Medical records | 690 | Persons diagnosed with sarcoidosis | Cases: 45.6 (mean), Comparators: 45.4 (mean) | 345 (50) | Caucasian, African-American, Asian, Native American, Other |
| van den Akker et al., 1998| Netherlands | 1993–1994 | 1.0 years | Medical records | 60,857 | General population | All ages | 31,227 (51) | Not specified |
| Wikström et al., 2015     | Finland | 1982–2002             | 10 years         | Self-reporting (questionnaire), clinical evaluations, laboratory values | 32,972 | General population | 25–64 | 17,068 (52) | Not specified |
| Wilson-Genderson et al., 2017 | USA         | 2006–2014             | 8 years          | Self-report (questionnaire) | 3,396 | General population | 50–74 | 2,080 (61) | White, African-American |

(continued)
Table 1 (continued)

| Study, year of publication | Country   | Data collection period | Follow-up period a | Data source | Sample size b | Population | Age, years (range) c | Female, n (%) | Ethnicity d |
|---------------------------|-----------|------------------------|-------------------|-------------|---------------|------------|----------------------|---------------|-------------|
| Xu et al., 2018           | Australia | 1996–2016              | 20 years          | Self-report (survey) | 11,941       | Women      | 45–50                | 11,941 (100)  | Not specified |
| Xu et al., 2019           | Australia | 1996–2016              | 20 years          | Self-report (survey) | 7,357       | Women      | 45–50                | 7,357 (100)   | Not specified |
| Xu et al., 2020           | Australia | 2010–2016              | 6 years           | Self-report (survey) | 5,107       | Women reporting premature ANM | 45–50 | 5,107 (100) | Not specified |
| Xu, Mishra & Jones, 2019  | Australia | 1996–2016              | 20 years          | Self-report (survey) | 6,398       | Women      | 45–50                | 6,398 (100)   | Not specified |

ANM, age at natural menopause; ART, antiretroviral therapy; HIV, human immunodeficiency virus; IR, incidence rate.

aAs provided by study authors as either mean or median years, or person-years. Group-specific mean (or median) follow-up periods are included for studies which did not report an overall mean or median follow-up period.

bWithout multimorbidity at baseline, as defined by study author(s).

cAge at baseline; reported as range or mean or median if an exact range was not reported.

dEthnicity is reported using terminology directly reported by study authors. Elaboration of ethnicities included in groups is provided where reported.

eThis age refers to the age of participants at baseline among all study participants irrespective of multimorbidity status as the age specific to participants without multimorbidity at baseline was not provided by authors.

fThis proportion of females refers to the proportion at baseline among all study participants irrespective of multimorbidity status as the proportion of females specific to participants without multimorbidity at baseline was not provided by authors.
| Study, year of publication | Country | Data collection period | Follow-up perioda | Data source | Sample size | Population | Age, years (range)b | Female, n (%) | Ethnicity                        |
|---------------------------|---------|------------------------|-------------------|-------------|-------------|------------|-------------------|---------------|----------------------------------|
| Ashworth et al., 2019     | United Kingdom | 2004–2018 | Not specified | Medical records | 332,353 | Primary care | ≥18 | 164,487 (49) | Black, South Asian, Mixed, Other, Unknown |
| Freising et al., 2020     | Denmark, France, Germany, Greece, Italy, Netherlands, Norway, Spain, Sweden, United Kingdom | 1992–2010 | 11.0 years (mean) | Self-report (questionnaire), medical records, health insurance records | 291,778 | General population | 43–58 (median) | 186,564 (64) | Not specified |
| Haug et al., 2020         | Austria | 2003–2014 | 12.0 years | Medical records | 5,112,811 | General population | All ages | Not specified | Not specified |
| Jørgensen et al., 2020    | Denmark | 1994–2016 | Not specified | Medical records | 73,213 | Persons with AD and VaD | AD: 80.32 (mean), VaD: 79.12 (mean) | 44,786 (61) | Not specified |
| Strauss et al., 2014      | United Kingdom | 2003–2005 | 3.0 years | Medical records | 9,160 | Primary care | 50–75 | 5,166 (56) | Not specified |

AD: Alzheimer’s disease; VaD: Vascular dementia.

a As provided by study authors as either mean or median years. Group-specific mean (or median) follow-up periods are included for studies which did not report an overall mean or median follow-up period.

b At baseline.
and sample sizes ranged from 9,160 and approximately 5 million. Comparable to studies reporting incidence of multimorbidity, study population ages ranged across the lifespan with most studying older adults only. One study reported race and ethnicity, and data were most commonly sourced from medical records.

**Incidence of multimorbidity**

The incidence of multimorbidity for the 32 incidence studies are reported in Table 3.

Among the 14 studies reporting IRs, rates were highly heterogeneous. Only five of the 14 studies reported an overall IR in addition to group-specific rates. Across studies reporting incidence, the median (unadjusted) incidence rate was 30.7 per 1,000 person-years (IQR 39.5 per 1,000 person-years) and the median (unadjusted) cumulative incidence was 2.8% (IQR 28.7%). Incidence rates ranged from 1.26 to 342 per 1,000 person-years. Of all incidence studies, two adjusted incidence for age, sex, and/or ethnicity. IRs across the lifespan increased with age, with studies of middle-aged to older participants (50+ years of age) reporting higher IRs than those consisting of younger and adult populations (0–40 years of age). Most studies did not stratify IRs by sex, with only one reporting IRs among male and female participants separately; this study reported a higher IR among women than in men. Of the 11 studies reporting race and/or ethnicity, five reported incidence rate(s) stratified by race and/or ethnicity, one adjusted incidence rates for race and/or ethnicity, and two presented both adjusted overall and stratified incidence rate(s) by race and/or ethnicity. Two studies consisting solely of South and East Asian ethnicities (Malay, Chinese, and Indian) reported higher IRs than the remaining studies reporting IRs in White, Non-White, Black/African-American, Hispanic, and Māori populations.

Cumulative incidences of multimorbidity are presented in Table 3. Of the 18 studies reporting cumulative incidence, 10 studies reported overall unadjusted cumulative incidence ranging from 1.3% to 61.0%. Group-specific values ranged between 0% of participants developing multimorbidity (expressed in a European study as development of four chronic conditions over 2-year follow-up) and 76.8% of participants developing multimorbidity (defined in an Australian study of women as development of two or more chronic conditions over 20-year follow-up). Amongst five studies of specific patient populations, three had higher cumulative incidence compared to those conducted in general populations.

Across studies reporting either incidence rate or cumulative incidence, studies of older (45+ years of age) populations reported higher cumulative incidence than those which included younger population (<21 years of age). Additionally, in studies which presented incidence stratified by baseline disease counts, persons with one chronic condition at baseline had higher incidence of multimorbidity by the end of study follow-up, compared to those with zero at baseline. With the exception of one studies including nine or more chronic conditions in their definition of multimorbidity reported higher incidence than those including fewer conditions.

**Patterns in accumulation of chronic conditions**

The five articles that studied the accumulation of chronic conditions varied in the methods used to determine patterns, format of reporting, and in the component chronic conditions making up multimorbidity (Table 4). Four studies reported overall pattern(s) in accumulation and, of these, only one reported additional patterns by demographic subgroups and one reported patterns in accumulation by starting condition among participants.

Three studies characterized the order of component chronic conditions as trajectories, one as transitions, and one as pathways. All but two studies reported patterns in accumulation of chronic conditions in populations of individuals with specific underlying diseases.

As reported by Ashworth et al., starting conditions varied by age, social deprivation, and ethnicity. For example, depression was more common as a starting condition in individuals under 65 years of age, while diabetes and CHD were more common in those 65+ years of age. Four studies reported hypertensive and heart diseases as among the common starting conditions resulting in later multimorbidity and two reported diabetes as the most common starting condition. Second and third conditions contributing to multimorbidity were highly variable amongst reported patterns; two studies indicated cerebrovascular diseases and mental health illness (i.e. mood disorders) as common second conditions resulting in multimorbidity status. This is in contrast to one study reporting a mental health illness (depression) as a common overall starting condition. Additional second- and third-component conditions reported include chronic pain, osteoarthritis, cancer, diabetes, and hypercholesterolemia.

**Methods in determining patterns in accumulation of chronic conditions**

There were diverse methods used by the five studies to determine and report the accumulation of component chronic conditions leading to multimorbidity; despite this diversity, each study reported their results diagrammatically.

Ashworth et al. employed alluvial plots, whereby the chronic conditions in the accumulation sequence are assigned to vertical axes. Bar heights of the vertical axes were used to represent the number of persons with a particular chronic condition, and the widths of “streams” joining bars were used to represent the number of persons in each adjoining pair of chronic conditions. Freising et al. identified chronic conditions and calculated hazard ratios
Table 3. Incidence of multimorbidity by study (n = 32).

| Study, year of publication | Group | Incidence | Adjustment |
|----------------------------|-------|-----------|------------|
| **Studies reporting incidence rates (n = 14)** | | | |
| Aminisani et al., 2019a | Overall | 68.5 per 1,000 person-years | Unadjusted |
| Bjur et al., 2019a | 1999 cohort | 2.56 per 1,000 person-years | Adjusted for age, sex, and ethnicity |
| Bjur et al., 2019a | 2004 cohort | 3.00 per 1,000 person-years | Adjusted for age, sex, and ethnicity |
| Bjur et al., 2019a | 2009 cohort | 3.35 per 1,000 person-years | Adjusted for age, sex, and ethnicity |
| Castilho et al., 2019a | Multiple | Varied between 11.87–14.97 per 1,000 person-years by age and length of follow-up period (1 to 11 years from study entry) | Unadjusted |
| Castilho et al., 2020a | Multiple | Varied between 24.0–51.5 per 1,000 person-years by age group (30 to 70+ years) | Unadjusted |
| Chan et al., 2019a | Multiple | Varied between 17.4–160.9 per 1,000 person-years by age group (45 to 85+ years) | Unadjusted |
| Dhalwani et al., 2016a | Overall | 59 per 1,000 person-years | Unadjusted |
| Dugravot et al., 2020a | Overall | 13.87 per 1,000 person-years | Unadjusted |
| Freisling et al., 2020a | Cancer to multimorbidity | 13 per 1,000 person-years | Unadjusted |
| Freisling et al., 2020a | CVD to multimorbidity | 31.3 per 1,000 person-years | Unadjusted |
| Freisling et al., 2020a | T2D to multimorbidity | 25.0 per 1,000 person-years | Unadjusted |
| Hussin et al., 2019a | Zero conditions at baseline | 1.37 per 1,000 person-years | Unadjusted |
| Hussin et al., 2019a | One condition at baseline | 34.2 per 1,000 person-years | Unadjusted |
| Kivimäki et al., 2017a | Overall | 1.26 per 1,000 person-years (cardiometabolic multimorbidity) | Unadjusted |
| Lau et al., 2019a | At 18 months follow-up | 237 per 1,000 person-years | Unadjusted |
| Lau et al., 2019a | At 36 months follow-up | 215 per 1,000 person-years | Unadjusted |
| Licher et al., 2019a | Overall | 20.7 per 1,000 person-years | Unadjusted |
| Melis et al., 2014a | Zero conditions at baseline | 126 per 1,000 person-years | Unadjusted |
| Melis et al., 2014a | One condition at baseline | 329 per 1,000 person-years | Unadjusted |
| St Sauver et al., 2015a | Women | 38.8 per 1,000 person-years | Adjusted by age and sex to the total US 2010 Decennial Census |
| St Sauver et al., 2015a | Men | 35.5 per 1,000 person-years | Adjusted by age and sex to the total US 2010 Decennial Census |
| **Studies reporting cumulative incidence (n = 18)** | | | |
| Demirchyan et al., 2013a | Overall | 61.0% over 22 years | Unadjusted |
| Guaraldi et al., 2015 | Overall | 9.7% over 3 years | Unadjusted |
| Hohmann et al., 2019a | Multiple | Varied between 0.3% and 5.4% by sex, birth cohort, length of follow-up period, and age group (4 to 20 years) (respiratory multimorbidity) | Unadjusted |
| Marengoni et al., 2018a | Control with zero chronic conditions at baseline | 16.5% over 2 years | Unadjusted |
| Marengoni et al., 2018a | Control with one chronic condition at baseline | 44% over 2 years | Unadjusted |
| Marengoni et al., 2018a | Intervention with zero chronic conditions at baseline | 10.8% over 2 years | Unadjusted |

(continued)
| Study, year of publication | Group | Incidence | Adjustment |
|----------------------------|-------|-----------|------------|
| Marengoni et al., 2018\(^a\) | Intervention with one chronic condition at baseline | 33.2% over 2 years | Unadjusted |
| Mounce et al., 2018\(^a\) | Zero conditions at baseline | 25.5% over 10.1 years | Unadjusted |
| Mounce et al., 2018\(^a\) | One condition at baseline | 65.3% over 10.1 years | Unadjusted |
| Niedzwiedz et al., 2018 | Overall | 30.3% over 6 years | Unadjusted |
| Ryan et al., 2018\(^a\) | Overall | 30.4% over 2 years | Unadjusted |
| Salloum et al., 2019\(^a\) | Cohort diagnosed with medulloblastoma in 1970s | 12.2% over 15 years | Unadjusted |
| Salloum et al., 2019\(^a\) | Cohort diagnosed with medulloblastoma in 1980s | 19.6% over 15 years | Unadjusted |
| Singh-Manoux et al., 2018\(^a\) | Overall | 6.18% over 23.7 years (cardiometabolic multimorbidity) | Unadjusted |
| Tomasdottir et al., 2016\(^a\) | Overall | 30.8% over 11 years | Unadjusted |
| Ungprasert et al., 2017\(^a\) | Referent (non-sarcoidosis participants) | 31.7% over 15.6 years (median) | Unadjusted |
| Ungprasert et al., 2017\(^a\) | Participants with sarcoidosis | 45.5% over 12.9 years (median) | Unadjusted |
| van den Akker et al., 1998\(^a\) | Overall | 1.3% over 1 year | Unadjusted |
| Wikström et al., 2015 | Women with zero conditions at baseline | 1% over 10 years | Unadjusted |
| Wikström et al., 2015 | Men with zero conditions at baseline | 2% over 10 years | Unadjusted |
| Wikström et al., 2015 | Women with DM at baseline | 22.6% over 10 years | Unadjusted |
| Wikström et al., 2015 | Men with DM at baseline | 30.8% over 10 years | Unadjusted |
| Wikström et al., 2015 | Women with CVD at baseline | 24% over 10 years | Unadjusted |
| Wikström et al., 2015 | Men with CVD at baseline | 23.3% over 10 years | Unadjusted |
| Wilson-Genderson et al., 2017\(^a\) | Overall | 41.6% over 12 years (by T4) | Unadjusted |
| Xu et al., 2018\(^a\) | Overall | 16.8% over 20 years | Unadjusted |
| Xu et al., 2019\(^a\) | Overall | 60.4% over 20 years | Unadjusted |
| Xu et al., 2020\(^a\) | Multiple | Varied between 35.9% and 66.7% by age group at natural menopause (≤40 to ≥54 years) | Unadjusted |
| Xu, Mishra & Jones, 2019\(^a\) | Control (women without DEP) | 52.6% over 18 years | Unadjusted |
| Xu, Mishra & Jones, 2019\(^a\) | Women with DEP | 76.8% over 18 years | Unadjusted |

ANM, age at natural menopause; BMI, body mass index; CVD, cardiovascular disease; DEP, depression; DM, diabetes mellitus; HIV, human immunodeficiency virus; T2D, type II diabetes.

\(^a\)Additional incidence rate(s) and/or cumulative incidence available in study text.
for movement from one starting condition to another, reported as the number of cases per 1,000 person-years. Separate pathway diagrams representing acquisition sequencing of three conditions were presented.

Haug et al.\(^{118}\) employed machine learning to develop trajectories for risk of cardiovascular mortality based on divisive cluster analysis, in which all persons started in the same cluster and were algorithmically divided into different clusters according to the chronic conditions acquired over time. The study presented cluster trajectories as a multilayer network diagram.

Jørgensen et al.\(^{111}\) examined pre-dementia temporal accumulation of multimorbidity for persons with Alzheimer’s disease and vascular dementia. Disease pairs were examined to determine which condition came first. The relative risk for acquiring the second condition for those with dementia compared to matched controls, was calculated. In addition to relative risks, the study presented temporal disease trajectory networks of diagnoses for persons with dementia, where each condition is a node joined by lines that indicate accumulation pathways.

Strauss et al.\(^{25}\) conducted a latent class growth analysis to identify distinct multimorbidity trajectories. The analysis began with a one-cluster model (all persons having the same trajectory). The number of clusters was increased until most heterogeneity was explained. Quadratic growth curves were applied, and persons were assigned to a cluster in which their posterior probability of membership was

---

Table 4. Patterns in accumulation of component chronic conditions in multimorbidity and methods used to ascertain patterns (n = 5).

| Study, year of publication | Patterns in accumulation |
|----------------------------|--------------------------|
| Ashworth et al., 2019      | Overall: Diabetes and depression were the most common starting conditions. Chronic pain was more common as a second or third acquired condition. |
|                           | Age: Under 65 years, the most common starting condition was depression. In 65+ years, the most common starting conditions were diabetes and CHD. |
|                           | Deprivation: In most deprived, the most common starting conditions were diabetes and depression. In least deprived, the most common starting conditions were diabetes and CHD. |
|                           | Ethnicity: Among Black participants, diabetes was the most common starting condition; serious mental illness and depression were also common starting conditions. Among White participants, depression was the most common starting condition. |
| Freisling et al., 2020     | Cancer: Transitions to multimorbidity through acquiring CVD or T2D at 6.5 events/1,000 person-years. |
|                           | CVD: Transition to multimorbidity through acquiring cancer at 16.6 events/1,000 person-years and through acquiring T2D at 14.7 events/1,000 person-years. |
|                           | T2D: Transition to multimorbidity through acquiring cancer at 14.3 events per 1,000 person-years and through acquiring CVD at 10.7 events/1,000 person-years. |
| Haug et al., 2020          | Overall: 132 clusters of chronic conditions (ICD-10 diagnoses) identified with cluster 0 (no known prior diagnoses) a beginning healthy state for participants. Reduced disease trajectory was defined by accumulation of additional clusters over time, with time period where no new clusters accumulated were removed. |
|                           | Cerebrovascular disease: More than 50% followed reduced trajectories of length greater than two. |
|                           | Most frequent reduced trajectory of length 3 is (0, 114, 123); patients from healthy cluster 0 move to cluster 114 (hypertensive diseases I10–I15 and heart diseases I30–I52) to cluster 123 where cerebrovascular diseases become included (cluster 123). Malignant neoplasms: More than 50% only visit two different clusters, and 44% of those had reduced trajectory (0, 55), healthy cluster to a cancer cluster. Most frequent reduced trajectory of length 3, was 0, 55, 109, where patients acquire hypertensive diseases (I10–I15) after cancer. |
| Jørgensen et al., 2020     | Mood disorders: 9.5% ended their trajectory in cluster 71 where, additional to mood disorders, they were diagnosed with mental and behavioral disorders due to psychoactive substance use (F10–F19). |
|                           | Overall: For both types of dementia, many trajectories contained F03 “Unspecified dementia” and subsequently F00 “Dementia in Alzheimer disease.” E10 “Type I diabetes mellitus” and E11 “Type II diabetes mellitus” are common paths toward a dementia diagnosis, as are cardiovascular diseases like I10 “Hypertension,” I20 “Angina pectoris,” and I50 “Heart failure.” |
|                           | Alzheimer’s Disease: 50 significant directional trajectories consisting of three consecutive diseases. |
|                           | Vascular Dementia: 215 significant directional trajectories consisting of three consecutive diseases. |
| Strauss et al., 2014       | Overall: Five trajectories identified: 1) those with no recorded chronic problems; 2) those who developed first chronic morbidity over 3 years; 3) developing multimorbidity group characterized by progressing from zero or one chronic morbidity at the first period to two or three by the sixth period; 4) those with increasing number of chronic morbidities; and 5) multi-chronic group with many chronic morbidities. The most common trajectories started with hypertension in the first period and developed osteoarthritis, diabetes mellitus, and/or pure hypercholesterolemia over the six periods. |

CHD: coronary heart disease; CVD: Cardiovascular disease; ICD-10: International Classification of Diseases, version 10.
highest. The trajectories of numbers of accumulating conditions were presented graphically using latent class growth trajectories.

Discussion

This systematic review contributes to a growing body of literature concerning the epidemiology of multimorbidity by providing a comprehensive, qualitative analysis of multimorbidity incidence and patterns in the accumulation of chronic conditions. The purpose of most included studies was to determine the incidence of multimorbidity and/or accumulation of component chronic conditions leading to multimorbidity. However, nine studies had other primary objectives and were able to opportunistically examine incidence.111,112,116,119,122,123,134,136,141

Of the 32 studies reporting incidence, five studies reported overall IRs ranging from 1.26 to 68.5 per 1,000 person-years, and 10 studies reported overall cumulative incidence ranging from 1.3% to 61.0%. The wide variation among incidence estimates in these 15 studies may be attributed to differences in: study populations being examined, with some sampling general populations and others sampling patient populations with specific baseline conditions; age and race or ethnicities of study participants; follow-up duration; as well as a lack of uniformity in the criteria that were used to define multimorbidity. The remaining 17 incidence studies reported incidence stratified by sociodemographic and medical factors. This helps elucidate factors impacting multimorbidity; however, it would facilitate comparisons across studies if authors report, where possible, overall rates adjusted for factors known to be associated with multimorbidity, including (at minimum) age, sex/gender, and number of baseline conditions.58,142 Only two studies in this review adjusted overall incidence for age and sex.129,130

The findings from this review regarding the relationship between multimorbidity and the number of baseline chronic condition(s), age, and sex generally aligned with previous literature. In studies which presented incidence stratified by baseline disease counts, persons with one chronic condition at baseline had higher incidence of multimorbidity later in life, compared to those with zero at baseline. This may be due in part to underlying genetic mechanisms of chronic diseases143; systemic health impacts of chronic conditions in diagnosed individuals144; and/or persons with a baseline chronic condition being more likely to seek medical help,145 and therefore more likely to be diagnosed with other illnesses unrelated to the initial illness. Both incidence rates and cumulative incidence were higher in older populations, consistent with the well-documented relationship between age and multimorbidity.146–148

Amongst studies reporting incidence by sex, IRs and cumulative incidence were higher for women than men. This relationship between sex and multimorbidity is consistent with literature indicating that women may be more likely to be diagnosed with chronic conditions because they are more likely to seek medical help149–152 and have higher life expectancies than men.142,153,154

Of all identified studies reporting patterns in the accumulation of multimorbidity’s component chronic conditions, only five studies met our selection criteria. This review indicates distinct patterns in accumulation of chronic conditions, as reported by studies elucidating cardiovascular and metabolic conditions amongst the most common starting conditions, and cerebrovascular and mental illnesses as common second conditions resulting in multimorbidity. Together, cardiometabolic conditions including stroke, heart disease, and diabetes, contribute to leading causes of morbidity, mortality, lower quality of life, and health resource use globally.117,155–157 Understanding disease trajectories as discussed in this review may help clinicians identify persons at greater risk of developing such conditions and better understand their prognosis in order to effectively prevent and manage this set of diseases. Depression was noted as a common starting condition in persons below 65 years of age, which may be attributed in part to cultural trends in digital and communication media, sleep deprivation, and social deprivation in younger persons, contributing to rising rates of mood disorders and suicidal thoughts and behaviors since the mid-2000s, factors which may have a greater impact on younger persons compared to older generations.107,158 This result was found only in one study in accumulation, demonstrating the need for future research to confirm these findings in other populations. There is significant diversity in the definition of “patterns” in multimorbidity research, with some studies employing a temporal component25,107,111,117,118 and others using the term almost synonymously with patient clusters.60 Methods used to discern accumulation were highly heterogeneous and showed novel applications of advanced statistical techniques. A common feature of the five articles was the use of diagrams to demonstrate temporal relationships. Ongoing innovation in this area bodes well for future research that examines the accumulation of component chronic conditions in multimorbidity and may inform preventative efforts.

We identified articles that used the term accumulation differently than we had initially set out in our objectives, which was to examine the order of chronic condition accumulation leading to an individual having multimorbidity. As such, we excluded studies that measured speed of accumulation of chronic conditions46 and those that measured accumulation as most commonly occurring incident dyads and triads of chronic conditions without consideration for order or disease onset.130 However, this diversity in the definition of accumulation can add to the richness of understanding multimorbidity incidence, and therefore an in-depth examination taking into account all aspects and forms of accumulation reported across the literature is warranted.
Our review found limitations in the included studies with respect to age, sex and gender, and race and ethnicity. The study of multimorbidity is heavily focused toward adult and elderly populations; however, incidence of multimorbidity amongst children and adolescents who have chronic conditions warrants more attention given their increased risk of developing additional diseases later in life. Additionally, most studies reported patterns by chronic conditions and only one reported patterns by demographic factors, such as age.

All studies in our review were not explicit in their definitions of sex and gender. Such studies are failing to define sex and gender as non-binary variables when studying the health of populations. Among studies that reported race and/or ethnicity, data were collected from different sources ranging from medical records to self-report. The COVID-19 pandemic underscored the importance of calculating race and ethnic-specific incidence of multimorbidity. Routine collection of these data is a necessary step to understanding the role of race and/or ethnicity in multimorbidity incidence.

The findings from our systematic review demonstrate heterogeneity across studies with respect to incidence of multimorbidity and with respect to the order in which component chronic conditions that lead to multimorbidity were accumulated. This is consistent with reviews reporting the prevalence of multimorbidity for similar reasons as have been found in these prevalence studies. The heterogeneity across articles may be due in part to diverse study objectives, study designs, and operational definitions for multimorbidity across the included studies. More specifically, the widely varying number and selection of chronic conditions contributing to the definition of multimorbidity poses significant challenges to the comparison of findings among studies. For example, there is well-established evidence that hypertension is a precursor to multimorbidity in adult populations; however, some studies did not include hypertension in their definition of multimorbidity. This finding may be the result of specific studies’ consideration of hypertension as a risk factor and not as a disease.

While study specificity in design or operational definition of multimorbidity may allow for more targeted study of multimorbidity within a given population, it contributes to the complexity of comparing incidence and accumulation of multimorbidity across studies. Given the heterogeneity among incidence studies, authors should be transparent in reporting results. At minimum, authors should explicitly state their definition of multimorbidity, clearly indicating the number of co-occurring conditions required to define multimorbidity, and the number and selection of chronic conditions included in their list of component chronic conditions. Additionally, where the available data permit, studies are encouraged to limit defining conditions of multimorbidity to five relevant chronic conditions, including those with well-established links to increased risk of multimorbidity development, including cardiovascular diseases, hypertension, and diabetes.

This systematic review studied the incidence of multimorbidity and patterns in accumulation of chronic conditions across the lifespan, including children. Our consideration of all age groups is a strength of this review in light of evidence demonstrating the onset of a number of morbidities at younger ages; possibilities for illnesses to transition to chronic status; and the value of early identification in timely intervention and mitigating disease progression. In addition, incidence rates were stratified by reporting format (IR or cumulative incidence) for more accurate comparison among study findings. This review was conducted in accordance with PROSPERO guidelines by two reviewers, with title and abstract screening, full-text review, data extraction, and quality assessment of studies completed independently. Included studies were mostly of high quality in accordance with the NOS, AHRQ, and Cochrane RoB criteria.

An inherent limitation amongst all systematic reviews is the omission of potentially relevant articles. Due to our inclusion criteria requiring articles to be of either English or French language, 122 non-English/French studies were excluded early in the review process without consideration for inclusion, some of which may have been relevant to our study. In addition, studies of low quality in reporting were not excluded to ensure the full spectrum of literature in multimorbidity was included in this review. This may have impacted the accuracy of these studies’ estimates. For example, studies which scored low on representativeness may produce estimates that do not represent the true estimates for their target population; however, it is not possible to discern whether such estimates are inflated or deflated. Similarly, studies which scored low on reporting outcome assessment may have estimates lower than actual because they did not adequately capture every occurrence of multimorbidity. Finally, while studies in this review reported on chronic conditions or non-communicable diseases, three studies also included a small count of acute conditions in their definitions and four did not specify a definition of multimorbidity (Supplementary Table S6). Despite the lack of explicit definition of multimorbidity in these studies, we were confident in including their work given reference to 2+ conditions in prose and/or tables.

### Conclusion

Establishing the incidence of multimorbidity is a critical step in understanding the etiology and informing prevention of multimorbidity in general and specific patient populations across the lifespan. This systematic review of 36 studies presents that nearly 31 per 1,000 person-years (IQR 39.5 per 1,000 person-years) and 3% (IQR 28.7%) of the studied populations included in this review are affected by multimorbidity, and that component chronic conditions...
contributing to the development of multimorbidity are highly heterogeneous. We recommend that researchers be transparent in reporting the components of their operational definitions of multimorbidity, and that patterns in multimorbidity be differentiated by age group and sex and/or gender to allow more specific analyses of the incidence of multimorbidity, and its implication for health care and health systems. Our findings support the importance of work underway to determine a standardized operational definition of multimorbidity. These practices will allow for more accurate comparison and estimation of the incidence and progression of multimorbidity, and subsequently, more effective disease management and preventative interventions across all stages of life.

Authors' note
Banafsheh Salimarouny and Prtha Kudesia are joint first authors.

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iDs
Prtha Kudesia https://orcid.org/0000-0001-9080-5635
Martin Fortin https://orcid.org/0000-0002-9874-3771
Bridget L Ryan https://orcid.org/0000-0001-9080-5635

Supplemental material
Supplemental material for this article is available online.

References
1. Battegay E. Multimorbidity is a game changer. Swiss Med Wkly. https://doi.emh.ch/smw.2019.20131 (2019, accessed 12 December 2020).
2. Pearson-Stuttard J, Ezzati M and Gregg EW. Multimorbidity—a defining challenge for health systems. Lancet Public Health 2019; 4(12): e599–e600.
3. Boyd CM and Fortin M. Future of multimorbidity research: how should understanding of multimorbidity inform health system design? Public Health Rev 2010; 32(2): 451–474.
4. Canadian Institute for Health Information. Seniors and the health care system: what is the impact of multiple chronic conditions. Toronto: Canadian Institute for Health Information, 2011.
5. Ryan B, Allen B, Zwarenstein M, et al. Multimorbidity and mortality in Ontario, Canada: a population-based retrospective cohort study. J Comorb 2020; 10: 1–10.
6. Lund Jensen N, Pedersen HS, Vestergaard M, et al. The impact of socioeconomic status and multimorbidity on mortality: a population-based cohort study. Clin Epidemiol 2017; 9: 279–289.
7. Hanlon P, Nicholl BJ, Jani BD, et al. Frailty and pre-frailty in middle-aged and older adults and its association with multimorbidity and mortality: a prospective analysis of 493 737 UK Biobank participants. Lancet Public Health 2018; 3(7): e323–e332.
8. Randall DA, Lujic S, Havard A, et al. Multimorbidity among aboriginal people in new south wales contributes significantly to their higher mortality. Med J Australia 2018; 209(1): 19–23.
9. Singh K, Patel SA, Biswas S, et al. Multimorbidity in South Asian adults: prevalence, risk factors and mortality. J Public Health (Oxf) 2019; 41(1): 80–89.
10. Stanley J, Semper K, Millar E, et al. Epidemiology of multimorbidity in New Zealand: a cross-sectional study using national-level hospital and pharmaceutical data. BMJ Open 2018; 8(5): e021689.
11. Willadsen TG, Siersma V, Nicolaisdottir DR, et al. Multimorbidity and mortality: a 15-year longitudinal registry-based nationwide Danish population study. J Comorb 2018; 8(1): 2235042X18804063.
12. Jani BD, Hanlon P, Nicholl BI, et al. Relationship between multimorbidity, demographic factors and mortality: findings from the UK Biobank cohort. BMC Med 2019; 17(1): 74.
13. DuGoff EH, Canadas-Romo V, Bupport C, et al. Multiple chronic conditions and life expectancy: a life table analysis. Med Care 2014; 52(8): 688–694.
14. Nunes BP, Flores TR, Mielke GI, et al. Multimorbidity and mortality in older adults: a systematic review and meta-analysis. Arch Gerontol Geriatr 2016; 67: 130–138.
15. Leme DE da C, Thomaz RP, Borim FSA, et al. Survival of elderly outpatients: effects of frailty, multimorbidity and disability. Cien Saude Colet 2019; 24(1): 137–146.
16. Ibarra-Castillo C, Giusado-Clavero M, Violan-Fors C, et al. Survival in relation to multimorbidity patterns in older adults in primary care in Barcelona, Spain (2010-2014): a longitudinal study based on electronic health records. J Epidemiol Commun Health 2018; 72(3): 185–192.
17. Nguyen QD, Wu C, Olden MC, et al. Multimorbidity patterns, frailty, and survival in community-dwelling older adults. J Gerontol A Biol Sci Med Sci 2019; 74(8): 1265–1270.
18. Rivera-Almaraz A, Manrique-Espinoza B, Ávila-Funes JA, et al. Disability, quality of life and all-cause mortality in older Mexican adults: association with multimorbidity and frailty. BMC Geriatr 2018; 18(1): 236.
19. Schäfer I, Kaduszkiwicz H, Nguyen TS, et al. Multimorbidity patterns and 5-year overall mortality: Results from a claims data-based observational study. J Comorb 2018; 8(1): 2235042X18816588.
20. Wei MY, Kabeto MU, Galecki AT, et al. Physical functioning decline and mortality in older adults with multimorbidity: joint modeling of longitudinal and survival data. J Gerontol A Biol Sci Med Sci 2019; 74(2): 226–232.
21. Salisbury C, Johnson L, Purdy S, et al. Epidemiology and impact of multimorbidity in primary care: a retrospective cohort study. Br J Gen Pract 2011; 61(582): e12–e21.
22. Huntley AL, Johnson R, Purdy S, et al. Measures of multimorbidity and morbidity burden for use in primary care and community settings: a systematic review and guide. *Ann Fam Med* 2012; 10(2): 134–141.

23. Muggah E, Graves E, Bennett C, et al. The impact of multiple chronic diseases on ambulatory care use; a population based study in Ontario, Canada. *BMC Health Serv Res* 2012; 12(1): 452.

24. Rosella LC, Fitzpatrick T, Wodchis WP, et al. High-cost health care users in Ontario, Canada: demographic, socioeconomic, and health status characteristics. *BMC Health Serv Res* 2014; 14(1): 532.

25. Strauss VY, Jones PW, Kadam UT, et al. Distinct trajectories of multimorbidity in primary care were identified using latent class growth analysis. *J Clin Epidemiol* 2014; 67(10): 1163–1171.

26. Fortin M, Stewart M, Poitras M-E, et al. A systematic review of prevalence studies on multimorbidity: toward a more uniform methodology. *Ann Fam Med* 2012; 10(2): 142–151.

27. Smith SM, Soubhi H, Fortin M, et al. Managing patients with multimorbidity: systematic review of interventions in primary care and community settings. *BMJ* 2012; 345: e5205.

28. Nguyen H, Manolova G, Daskalopoulou C, et al. Prevalence of multimorbidity in community settings: a systematic review and meta-analysis of observational studies. *J Comorb* 2019; 9: 2235042X1987093.

29. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Int J Surg* 2010; 8(5): 336–341.

30. Lefebvre C, Glanville J, Briscoe S, et al. Chapter 4. Searching for and selecting studies. In: Higgins J, Thomas J, Chandler J, Cumpston M, Li T, and Page M. (eds). *Cochrane Handbook for Systematic Reviews of Interventions version 6.1*. London: Cochrane, 2020. www.training.cochrane.org/handbook (updated September 2020, accessed 15 May 2020).

31. Wells M, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: University of Ottawa, http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed 23 January 2021).

32. Higgins JPT, Altman DG, Gotzsche PC, et al. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. *BMJ* 2011; 343: d5928.

33. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *PLoS Med* 2021; 18(3): e1003583.

34. Hussain R, Wark S, Janicki MP, et al. Multimorbidity in older people with intellectual disability. *J Appl Res Intellect Disabil* 2020; 33(6): 1234–1244.

35. Lange-Maia BS, Karvonen-Gutierrez CA, Kazlauskaite R, et al. Impact of chronic medical condition development on longitudinal physical function from mid- to early late-life: the study of women’s health across the nation. *Magaziner J*, editor. *J Gerontol Ser A* 2020; 75(7): 1411–1417.

36. Nguyen H, Chua K-C, Dregan A, et al. Factors associated with Multimorbidity patterns in older adults in England: findings from the English longitudinal study of aging (ELSA). *J Aging Health* 2020; 32(9): 1120–1132.

37. Yao S-S, Cao G-Y, Han L, et al. Prevalence and patterns of multimorbidity in a nationally representative sample of older chinese: results from the china health and retirement longitudinal study. *Newman A*, editor. *J Gerontol Ser A* 2020; 75(10): 1974–1980.

38. Timmermans EJ, Hoogendijk EO, Broese van Groenou MI, et al. Trends across 20 years in multiple indicators of functioning among older adults in the Netherlnds. *Eur J Public Health* 2019; 29(6): 1096–1102.

39. Gomis-Pastor M, Roig Mingell E, Mirabet Perez S, et al. Multimorbidity and medication complexity: New challenges in heart transplantation. *Clin Transplant* 2019; 33(10): e13682.

40. Juul-Larsen HG, Christensen LD, Bandholm T, et al. Patterns of multimorbidity and differences in healthcare utilization and complexity among acutely hospitalized medical patients (≥65 years)—a latent class approach. *Clin Epidemiol* 2020; 12: 245–259.

41. Kuan V, Denaxas S, Gonzalez-Izquierdo A, et al. A chronological map of 308 physical and mental health conditions from 4 million individuals in the English National Health Service. *Lan Digital Health* 2019; 1(2): e63–e77.

42. Calderón-Larrañaga A, Vetran DL, Welmer A-K, et al. Psychological correlates of multimorbidity and disability accumulation in older adults. *Age Ageing* 2019; 48(6): 789–796.

43. Juul-Larsen HG, Andersen O, Bandholm T, et al. Differences in function and recovery profiles between patterns of multimorbidity among older medical patients the first year after an acute admission—an exploratory latent class analysis. *Arch Gerontol Geriatr* 2020; 86: 103956.

44. Kristensen K, König H and Hajek A. The longitudinal association of multimorbidity on loneliness and network size: findings from a population-based study. *Int J Geriatr Psychiatry* 2019; 34(10): 1490–1497.

45. Gellert P, von Berenberg P, Zahn T, et al. Multimorbidity profiles in German centenarians: a latent class analysis of health insurance data. *J Aging Health* 2019; 31(4): 580–594.

46. Dekhtyar S, Vetran DL, Marengoni A, et al. Association between speed of multimorbidity accumulation in old age and life experiences: a cohort study. *Am J Epidemiol* 2019; 188(9): 1627–1636.

47. Hajek A, Brettschneider C, Eisele M, et al. Does transpersonal trust moderate the association between chronic conditions and general practitioner visits in the oldest old? Results of the AgeCoDe and AgeQualiDe study. *Geriatr Gerontol Int* 2019; 19(8): 705–710.

48. Maciejewski ML and Hammill BG. Measuring the burden of multimorbidity among Medicare beneficiaries via condition counts and cumulative duration. *Health Serv Res* 2019; 54(2): 484–491.

49. Quijones AR, Botoseneanu A, Markwardt S, et al. Racial/ethnic differences in multimorbidity development and
chronic disease accumulation for middle-aged adults. Ginsberg SD, editor. *PLoS One* 2019; 14(6): e0218462.

50. Lai FTT, Guthrie B, Wong SYS, et al. Sex-specific intergenerational trends in morbidity burden and multimorbidity status in Hong Kong community: an age-period-cohort analysis of repeated population surveys. *BMJ Open* 2019; 9(1): e023927.

51. Tran J, Norton R, Conrad N, et al. Patterns and temporal trends of comorbidity among adult patients with incident cardiovascular disease in the UK between 2000 and 2014: a population-based cohort study. *PLoS Med* 2018; 15(3): e1002513.

52. Schramm D, Reuter M, Grabenhenrich LB, et al. What does lung function tell us about respiratory multimorbidity in childhood and early adulthood? Results from the MAS birth cohort study. *Pediatr Allergy Immunol* 2018; 29(5): 481–489.

53. Sakib MN, Shooshatri S, St John P, et al. The prevalence of multimorbidity and associations with lifestyle factors among middle-aged Canadians: an analysis of Canadian Longitudinal Study on Aging data. *BMC Public Health* 2019; 19(1): 243.

54. Lebenbaum M, Zarić GS, Third A, et al. Trends in obesity and multimorbidity in Canada. *Prevent Med* 2018; 116: 173–179.

55. Wang J-H, Wu Y-J, Tee BL, et al. Medical comorbidity in Alzheimer’s disease: a nested case-control study. *J Alzheimers Dis* 2018; 63(2): 773–781.

56. Rosella L, Kornas K, Huang A, et al. Accumulation of chronic conditions at the time of death increased in Ontario from 1994 to 2013. *Health Aff* 2018; 37(3): 464–472.

57. Humphreys J, Jameson K, Cooper C, et al. Early-life predictors of future multimorbidity: results from the Hertfordshire Cohort. *Age Ageing* 2018; 47(3): 474–478.

58. Calderón-Larrañaga A, Santoni G, Wang HX, et al. Rapidly developing multimorbidity and disability in older adults: does social background matter? *J Intern Med* 2018; 283(5): 489–499.

59. Kingston A, Robinson L, Booth H, et al. Projections of multimorbidity in the older population in England to 2035: estimates from the Population Ageing and Care Simulation (PACSim) model. *Age Ageing* 2018; 47(3): 374–380.

60. Wong C, Gange SJ, Moore RD, et al. Multimorbidity among persons living with human immunodeficiency virus in the United States. *Clin Infect Dis* 2018; 66(8): 1230–1238.

61. Gu J, Chao J, Chen W, et al. Multimorbidity and health-related quality of life among the community-dwelling elderly: a longitudinal study. *Arch Gerontol Geriatr* 2018; 74: 133–140.

62. Canizares M, Hogg-Johnson S, Gignac MAM, et al. Increasing trajectories of multimorbidity over time: birth cohort differences and the role of changes in obesity and income. *J Gerontol B Psychol Sci Soc Sci* 2018; 73(7): 1303–1314.

63. Alaeddin A, Jaramillo CA, Faruqui SHA, et al. Mining major transitions of chronic conditions in patients with multiple chronic conditions. *Methods Inf Med* 2017; 56(05): 391–400.

64. Rocca WA, Gazzuola Rocca L, Smith CY, et al. Cohort profile: the mayo clinic cohort study of oophorectomy and aging-2 (MOA-2) in Olmsted County, Minnesota (USA). *BMJ Open* 2017; 7(11): e018861.

65. Admon LK, Winkelman TNA, Moniz MH, et al. Disparities in chronic conditions among women hospitalized for delivery in the United States, 2005-2014. *Obstet Gynecol* 2017; 130(6): 1319–1326.

66. Katikireddi SV, Skivington K, Leyland AH, et al. The contribution of risk factors to socioeconomic inequalities in multimorbidity across the life course: a longitudinal analysis of the Twenty-07 cohort. *BMC Med* 2017; 15(1): 152.

67. Nagel A, Jungert A, Spinmeier A, et al. The impact of multimorbidity on resting metabolic rate in community-dwelling women over a ten-year period: a cross-sectional and longitudinal study. *J Nutr Health Aging* 2017; 21(7): 781–786.

68. Rocca WA, Gazzuola Rocca L, Smith CY, et al. Bilateral oophorectomy and accelerated aging: cause or effect? *J Gerontol A Biol Sci Med Sci* 2017; 72(9): 1213–1217.

69. Bapat S, Shapey J, Toma A, et al. Chronic subdural hematoma: a single-centre experience developing an integrated care pathway. *Br J Neurosurg* 2017; 31(4): 434–438.

70. Rocca WA, Gazzuola-Rocca L, Smith CY, et al. Accelerated Accumulation of multimorbidity after bilateral oophorectomy: a population-based cohort study. *Mayo Clin Proc* 2016; 91(11): 1577–1589.

71. van Oostrom SH, Gijksen R, Stirbu I, et al. Time trends in prevalence of chronic diseases and multimorbidity not only due to aging: data from general practices and health surveys. *PLoS One* 2016; 11(8): e0160264.

72. Weimann A, Dai D and Oni T. A cross-sectional and spatial analysis of the prevalence of multimorbidity and its association with socioeconomic disadvantage in South Africa: a comparison between 2008 and 2012. *Soc Sci Med* 2016; 163: 144–156.

73. Whitson HE, Johnson KS, Sloane R, et al. Identifying patterns of multimorbidity in older Americans: application of latent class analysis. *J Am Geriatr Soc* 2016; 64(8): 1668–1673.

74. Jackson CA, Dobson AJ, Tooth LR, et al. Lifestyle and socioeconomic determinants of multimorbidity patterns among mid-aged women: a longitudinal study. Chamberlain AM, editor. *PLoS One* 2016; 11(6): e0156804.

75. Kenzik KM, Kent EE, Martin MY, et al. Chronic condition clusters and functional impairment in older cancer survivors: a population-based study. *J Cancer Surviv* 2016; 10(6): 1096–1103.

76. Fabbi E, An Y, Zoli M, et al. Association between accelerated multimorbidity and age-related cognitive decline in older Baltimore longitudinal study of aging participants without Dementia. *J Am Geriatr Soc* 2016; 64(5): 965–972.

77. Dhalwani NN, O’Donovan G, Zaccardini F, et al. Long terms trends of multimorbidity and association with physical activity in older English population. *Int J Behav Nutr Phys Act* 2016; 13(1): 8.

78. Pavela G and Latham K. Childhood conditions and multimorbidity among older adults. *GERONB* 2016; 71(5): 889–901.
79. Canizares M, Gignac M, Hogg-Johnson S, et al. Do baby boomers use more healthcare services than other generations? Longitudinal trajectories of physician service use across five birth cohorts. *BMJ Open* 2016; 6(9): e013276.

80. Deckx L, van den Akker M, Metseners J, et al. Chronic diseases among older cancer survivors. *J Cancer Epidemiol* 2012; 2012: 1–7.

81. Kim H, Shin S and Zurlo KA. Sequential patterns of health conditions and financial outcomes in late life: evidence from the health and retirement study. *Int J Aging Hum Dev* 2015; 81(1–2): 54–82.

82. Luo J, Hendryx M, Safford MM, et al. Newly developed chronic conditions and changes in health-related quality of life in postmenopausal women. *J Am Geriatr Soc* 2015; 63(11): 2349–2357.

83. Jackson CA, Dobson A, Tooth L, et al. Body mass index and socioeconomic position are associated with 9-year trajectories of multimorbidity: a population-based study. *Prev Med* 2015; 81: 92–98.

84. Jackson CA, Jones M, Tooth L, et al. Multimorbidity patterns are differentially associated with functional ability and decline in a longitudinal cohort of older women. *Age Ageing* 2015; 44(5): 810–816.

85. Hsu H-C. Trajectories of multimorbidity and impacts on successful aging. *Exp Gerontol* 2015; 66: 32–38.

86. Vos R, van den Akker M, Boesten J, et al. Trajectories of multimorbidity: exploring patterns of multimorbidity in patients with more than ten chronic health problems in life course. *BMJ Fam Pract* 2015; 16: 2.

87. Fabbris E, An Y, Zoli M, et al. Aging and the burden of multimorbidity: associations with inflammatory and anabolic hormonal biomarkers. *J Gerontol: Series A* 2015; 70(1): 63–70.

88. O’Malley CD, Tran N, Zapalowski C, et al. Multimorbidity in women with and without osteoporosis: results from a large US retrospective cohort study 2004–2009. *Osteoporos Int* 2014; 25(8): 2117–2130.

89. Kendall CE, Wong J, Taljaard M, et al. A cross-sectional, population-based study measuring comorbidity among people living with HIV in Ontario. *BMJ Public Health* 2014; 14(1): 161.

90. Barile JP, Thompson WW, Zack MM, et al. Multiple chronic medical conditions and health-related quality of life in older adults, 2004–2006. *Prev Chronic Dis* 2013; 10: E162.

91. Lappenschaar M, Hommersom A, Lucas PJF, et al. Multilevel temporal Bayesian networks can model longitudinal change in multimorbidity. *J Clin Epidemiol* 2013; 66(12): 1405–1416.

92. Vanfleteren LEGW, Spruit MA, Groenen M, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2013; 187(7): 728–735.

93. Espino˜n Lorenzo P, Manrique-Arjia S, Ureña I, et al. Baseline comorbidities in patients with rheumatoid arthritis who have been prescribed biological therapy: a case control study. *Reumatol Clin* 2013; 9(1): 18–23.

94. Kim DJ, Westfall AO, Chamot E, et al. Multimorbidity Patterns in HIV-infected patients: the role of obesity in chronic disease clustering. *JAIDS J Acquir Immune Defic Syndr* 2012; 61(5): 600–605.

95. Aarts S, den Akker M, van Bosma H, et al. The effect of multimorbidity on health related functioning: temporary or persistent? Results from a longitudinal cohort study. *J Psychosom Res* 2012; 73(3): 211–217.

96. Freund T, Kunz CU, Ose D, et al. Patterns of multimorbidity in primary care patients at high risk of future hospitalization. *Populat Health Manage* 2012; 15(2): 119–124.

97. Quinones AR, Li J, Bennett JM, et al. How does the trajectory of multimorbidity vary across black, white, and mexican americans in middle and old age? *J Gerontol Ser B Psychol Sci Soc Sci* 2011; 66B(6): 739–749.

98. Schäfer I, von Leitner E-C, Schön G, et al. Multimorbidity patterns in the elderly: a new approach of disease clustering identifies complex interrelations between chronic conditions. *Ross JS, editor. PLoS One* 2010; 5(12): e15941.

99. Uijen AA and van de Lisdonk EH. Multimorbidity in primary care: prevalence and trend over the last 20 years. *Eur J Gen Pract* 2008; 14(Suppl 1): 28–32.

100. Raherison C, Ouaalaya E-H, Bernady A, et al. Comorbidities and COPD severity in a clinic-based cohort. *BMJ Pulm Med* 2018; 18(1): 117.

101. Goodwin BC, March S, Ireland MJ, et al. Geographic disparities in previously diagnosed health conditions in colorectal cancer patients are largely explained by age and area level disadvantage. *Front Oncol* 2018; 8: 372.

102. Levett T, Wright J and Fisher M. HIV and ageing: what the geriatrician needs to know. *Rev Clin Gerontol* 2014; 24(1): 10–24.

103. Prados-Torres A, Calderón-Larrañaga A, Hanco-Saavedra J, et al. Multimorbidity patterns: a systematic review. *J Clin Epidemiol* 2014; 67(3): 254–266.

104. Marengoni A, Rizzuto D, Wang H-X, et al. Patterns of chronic multimorbidity in the elderly population. *J Am Geriatr Soc* 2009; 57(2): 225–230.

105. Ng HS, Vitry A, Koczvara B, et al. Patterns of comorbidities in women with breast cancer: a Canadian population-based study. *Cancer Causes Control* 2019; 30(9): 931–941.

106. Ng R, Sutradhar R, Yao Z, et al. Smoking, drinking, diet and physical activity-modifiable lifestyle risk factors and their associations with age to first chronic disease. *Int J Epidemiol* 2020; 49(1): 113–130.

107. Ashworth M, Durbaba S, Whitney D, et al. Journey to multimorbidity: longitudinal analysis exploring cardiovascular risk factors and sociodemographic determinants in an urban setting. *BMJ Open* 2019; 9(12): e031649.

108. Demirchyan A, Khachatourian V, Armenian HK, et al. Short and long term determinants of incident multimorbidity in a cohort of 1988 earthquake survivors in Armenia. *Int J Equity Health* 2013; 12(1): 68.

109. Dhalwani NN, Zaccardi F, O’Donovan G, et al. Association between lifestyle factors and the incidence of...
multimorbidity in an older English population. *GERONA* 2016; 72(4): 528–534.
110. Hussin NM, Shahar S, Din NC, et al. Incidence and predictors of multimorbidity among a multiethnic population in Malaysia: a community-based longitudinal study. *Aging Clin Exp Res* 2019; 31(2): 215–224.
111. Jørgensen IF, Aguayo-Orozco A, Lademann M, et al. Age-stratified longitudinal study of Alzheimer’s and vascular dementia patients. *Alzheimer’s Dementia* 2020; 16(6): 908–917.
112. Lau H, Shahar S, Hussin N, et al. Methodology approaches and challenges in population-based longitudinal study of a neuroprotective model for healthy longevity: LRGS TUA methodology and challenge. *Geriatr Gerontol Int* 2019; 19(3): 233–239.
113. Mounce LTA, Campbell JL, Henley WE, et al. Predicting incident multimorbidity. *Ann Fam Med* 2018; 16(4): 322–329.
114. Tomasdottir MO, Sigurdsson JA, Petursson H, et al. Does ‘existential unease’ predict adult multimorbidity? Analytical cohort study on embodiment based on the Norwegian HUNT population. *BMJ Open* 2016; 6(11): e012602.
115. van den Akker M, Buntinx F, Metsemakers JF, et al. Multimorbidity in general practice: prevalence, incidence, and determinants of co-occurring chronic and recurrent diseases. *J Clin Epidemiol* 1998; 51(5): 367–375.
116. Marengoni A, Rizzato D, Fratiglioni L, et al. The Effect of a 2-year intervention consisting of diet, physical exercise, cognitive training, and monitoring of vascular risk on chronic morbidity-the FINGER randomized controlled trial. *J Am Med Dir Assoc* 2018; 19(4): 355–360.e1.
117. Freisling H, Viallon V, Lennon H, et al. Lifestyle factors and risk of multimorbidity of cancer and cardiometabolic diseases: a multinational cohort study. *BMC Med* 2020; 18(1): 5.
118. Haug N, Deichsinger C, Gyimesi M, et al. Risk of multimorbidity of cancer and cardiometabolic diseases. *Can J Public Health* 2019; 109(5–6): 845–854.
119. Wångström K, Lindström J, Harald K, et al. Clinical and lifestyle-related risk factors for incident multimorbidity: 10-year follow-up of Finnish population-based cohorts 1982–2012. *Eur J Intern Med* 2015; 26(3): 211–216.
120. Bjer KA, Wi C-I, Ryu E, et al. Epidemiology of children with multiple complex chronic conditions in a mixed Urban-Rural US community. *Hospital Pediatr* 2019; 9(4): 281–290.
121. St Sauver JL, Boyd CM, Grossardt BR, et al. Risk of developing multimorbidity across all ages in an historical cohort study: differences by sex and ethnicity. *BMJ Open* 2015; 5(2): e006413.
122. Wilson-Genderson M, Heid AR and Pruchno R. Onset of multiple chronic conditions and depressive symptoms: a life events perspective. Sands LP, editor. *Innovat Aging* 2017; 1(2): ixg022.
123. Aminisani N, Stephens C, Allen J, et al. Socio-demographic and lifestyle factors associated with multimorbidity in New Zealand. *Epidemiol Health* 2019; 42: e2020001.
124. Holmman C, Keller T, Gehring U, et al. Sex-specific incidence of asthma, rhinitis and respiratory multimorbidity before and after puberty onset: individual participant meta-analysis of five birth cohorts collaborating in MeDALL. *BMJ Open Resp Res* 2019; 6(1): e000460.
125. Melis R, Marengoni A, Angleman S, et al. Incidence and predictors of multimorbidity in the elderly: a population-based longitudinal study. Scuteri A, editor. *PLoS One* 2014; 9(7): e103120.
126. Ryan A, Murphy C, Boland F, et al. What is the impact of physical activity and physical function on the development of multimorbidity in older adults over time? A population-based cohort study. *J Gerontol Ser A* 2018; 73(11): 1538–1544.
based cohort study 1976 to 2013. *Mayo Clin Proc* 2017; 92(12): 1791–1799.

138. Xu X, Jones M and Mishra GD. Age at natural menopause and development of chronic conditions and multimorbidity: results from an Australian prospective cohort. *Hum Reprod* 2020; 35(1): 203–211.

139. Xu X, Mishra GD and Jones M. Depressive symptoms and the development and progression of physical multimorbidity in a national Cohort of Australian women. *Health Psychol* 2019; 38(9): 812.

140. Brunson JC. Alluvial Plots in ggplot2. [https://cran.r-project.org/web/packages/ggalluvial/vignettes/ggalluvial.html](https://cran.r-project.org/web/packages/ggalluvial/vignettes/ggalluvial.html) (2020, accessed 12 January 2021).

141. Chan MS, van den Hout A, Pujades-Rodriguez M, et al. Socio-economic inequalities in life expectancy of older adults with and without multimorbidity: a record linkage study of 1.1 million people in England. *Int J Epidemiol* 2019; 48(4): 1340–1351.

142. Abad-Díez JM, Calderón-Larranagna A, Poncel-Falcó A, et al. Age and gender differences in the prevalence and patterns of multimorbidity in the older population. *BMC Geriatr* 2014; 14(1): 75.

143. Barnes PJ. Mechanisms of development of multimorbidity in the elderly. *Eur Respir J* 2015; 45(3): 790–806.

144. Agustí AGN, Noguera A, Sauleda J, et al. Systemic effects of chronic obstructive pulmonary disease. *Eur Respir J* 2003; 21(2): 347–360.

145. Sin DD, Bell NR, Svenson LW, et al. The impact of follow-up physician visits on emergency readmissions for patients with asthma and chronic obstructive pulmonary disease: a population-based study. *Am J Med* 2002; 112(2): 120–125.

146. Britt HC, Harrison CM, Miller GC, et al. Prevalence and patterns of multimorbidity in Australia. *Med J Austr* 2008; 189(2): 72–77.

147. Taylor AW, Price K, Gill TK, et al. Multimorbidity - not just an older person’s issue. Results from an Australian biomedical study. *BMC Public Health* 2010; 10(1): 718.

148. Wolff JL, Starfield B and Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. *Arch Intern Med* 2002; 162(20): 2269.

149. Matheson FI, Smith KLW, Fazli GS, et al. Physical health and gender as risk factors for usage of services for mental illness. *J Epidemiol Community Health* 2014; 68(10): 971–978.

150. Nabalamba A and Millar Wayne J. Going to the doctor. *Health Rep* 2007; 18(1): 23–35.

151. Tjepkema M. Health care use among gay, lesbian and bisexual Canadians. *Health Rep* 2008; 19(1): 53–64.

152. Verhaak PFM, Heijmans MJWM, Peters L, et al. Chronic disease and mental disorder. *Soc Sci Med* 2005; 60(4): 789–797.

153. Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. *Lancet* 2012; 380(9836): 37–43.

154. Garcia-Olmos L, Salvador CH, Alberquilla Á, et al. Comorbidity patterns in patients with chronic diseases in general practice. *PLoS One* 2012; 7(2): e32141.

155. Deschênes SS, Kivimaki M and Schmitz N. Adverse childhood experiences and the risk of coronary heart disease in adulthood: examining potential psychological, biological, and behavioral mediators in the Whitehall II Cohort study. *JAHA* 2021; 10(10): e019013.

156. World Health Organization. *Global status report on non-communicable diseases 2014*. Geneva: World Health Organization, 2014.

157. Sattar N, Gill JMR and Alazawi W. Improving prevention strategies for cardiometabolic disease. *Nat Med* 2020; 26(3): 320–325.

158. Twenge JM, Cooper AB, Joiner TE, et al. Age, period, and cohort trends in mood disorder indicators and suicide-related outcomes in a nationally representative dataset, 2005–2017. *J Abnorm Psychol* 2019; 128(3): 185–199.

159. Dunlay SM and Chamberlain AM. Multimorbidity in older patients with cardiovascular disease. *Curr Cardiovasc Risk Rep* 2016; 10(1): 3.

160. Salive ME. Multimorbidity in older adults. *Epidemiol Rev* 2013; 35(1): 75–83.

161. Zhang L, Ma L, Sun F, et al. A multicenter study of multimorbidity in older adult inpatients in China. *J Nutr Health Aging* 2020; 24(3): 269–276.

162. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. *Arch Gen Psychiatry* 2005; 62(6): 593–602.

163. Maslow GR, Haydon AA, Ford CA, et al. Young adult outcomes of children growing up with chronic illness: an analysis of the national longitudinal study of adolescent health. *Arch Pediatr Adolesc Med* 2011; 165(3), http://archpedi.jamanetwork.com/article.aspx?doi=10.1001/archpediatrics.2010.287 (accessed 21 December 2020).

164. Cicero EC, Reisner SL, Merwin EI, et al. The health status and medical education: a cross-sectional study. *Am J Med* 2002; 112(2): 120–125.

165. Reisner SL and Hughto JMW. Comparing the health of non-binary and transgender adults in the United States. Garcia J, editor. *PLoS One* 2020; 15(2): e0228765.

166. Maslow GR, Haydon AA, Ford CA, et al. Young adult outcomes of children growing up with chronic illness: an analysis of the national longitudinal study of adolescent health. *Arch Pediatr Adolesc Med* 2011; 165(3), http://archpedi.jamanetwork.com/article.aspx?doi=10.1001/archpediatrics.2010.287 (accessed 21 December 2020).

167. Reisner SL and Hughto JMW. Comparing the health of non-binary and transgender adults in a nationwide non-probability sample. *PLoS One* 2019; 14(8): e0221583.

168. Laurencin CT and McClinton A. The COVID-19 Pandemic: a call to action to identify and address racial and ethnic disparities. *J Racial Ethn Health Disparities* 2020; 7(3): 398–402.

169. Webb Hooper M, Nápoles AM and Pérez-Stable EJ. COVID-19 and racial/ethnic disparities. *JAMA* 2020; 323(24): 2466.
pressure control among 223,286 hypertensive patients. *Int J Cardiol* 2014; 177(1): 202–208.

170. Sarkar C, Dodhia H, Crompton J, et al. Hypertension: a cross-sectional study of the role of multimorbidity in blood pressure control. *BMC Fam Pract* 2015; 16(1): 98.

171. Forman DE, Maurer MS, Boyd C, et al. Multimorbidity in older adults with cardiovascular disease. *J Am College Cardiol* 2018; 71(19): 2149–2161.

172. Glynn LG, Buckley B, Reddan D, et al. Multimorbidity and risk among patients with established cardiovascular disease: a cohort study. *Br J Gen Pract* 2008; 58(552): 488–494.

173. Teljeur C, Smith SM, Paul G, et al. Multimorbidity in a cohort of patients with type 2 diabetes. *Eur J Gen Pract* 2013; 19(1): 17–22.

174. Alonso-Morán E, Orueta JF, Esteban JIF, et al. The prevalence of diabetes-related complications and multimorbidity in the population with type 2 diabetes mellitus in the Basque Country. *BMC Public Health* 2014; 14(1): 1059.

175. Guthrie B and Ho I. Measuring and understanding Multimorbidity using routine data in the UK. In progress.